Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | S100B | P04271 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736020 | 0.86 | CA2 (0.50) | SKP2BRD4ALDH1A1CYP3A4TDP1 | |
| SCHEMBL14410521 | 0.83 | LMNA (0.42) | BRD4ALDH1A1TDP1PTPN1CA1 | |
| SCHEMBL7450435 | 0.82 | CA2 (0.50) | SKP2BRD4ALDH1A1TSHRPTPN1 | |
| Ammonia Solution, Strong SCHEMBL4821867 | 0.79 | SKP2 (0.56) | SKP2BRD4ALDH1A1CYP3A4TDP1 | |
| SCHEMBL12158313 | 0.79 | SKP2 (0.44) | SKP2BRD4ALDH1A1CYP3A4TDP1 | |
| SCHEMBL18398223 | 0.78 | CA1 (0.48) | BRD4ALDH1A1PTPN1CA1CA2 | |
| SCHEMBL1852602 | 0.78 | CA2 (0.48) | SKP2BRD4ALDH1A1CYP3A4TSHR | |
| SCHEMBL9027014 | 0.77 | SKP2 (0.57) | SKP2ALDH1A1CYP3A4TDP1TSHR | |
| SCHEMBL31634603 | 0.76 | SKP2 (0.73) | SKP2ALDH1A1CYP3A4TDP1TSHR | |
| SCHEMBL841783 | 0.76 | SKP2 (0.73) | SKP2ALDH1A1CYP3A4TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
| US-9572792-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9073888-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2491023-B1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20120328661-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2491023-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| WO-2011050054-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | MYC, BRD1, BRD3 | SKP2 1282/4885BRD4 7/4885ALDH1A1 4457/4885 |
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | SKP2 2524/4885BRD4 1319/4885ALDH1A1 2558/4885 |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | PTGER4, PTGER1, PTGER3 | SKP2 1254/4885BRD4 135/4885ALDH1A1 2357/4885 |
| US-20120328661-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | SKP2 2524/4885BRD4 1319/4885ALDH1A1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.